An experimental cancer drug made by Sanofi-Aventis SA helped patients with advanced breast tumors live more than 60 percent longer using a new method that stops diseased cells from healing themselves, a new study found.
The treatment, called BSI-201, shrank tumors and slowed new growth in a study of 116 patients with so-called triple- negative breast cancer, an aggressive disease that doesn’t respond to many treatments. Results were presented today at the American Society of Clinical Oncology in Orlando, Florida.
BSI-201 leads an emerging class of treatments known as PARP inhibitors. Most cancer treatments work by blasting DNA with chemotherapy or radiation. Cancer can fight back by using PARP enzymes to fix damaged strands of DNA. The new medicines are designed to block the enzymes and kill the cancer. Read more…
Source: Bloomberg.com
Tags: Breast Cancer, Cancer
